AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

GRAL · NASDAQ · Medical - Diagnostics & Research

GRAIL (GRAL)

Developer of Galleri and targeted methylation tools for cancer detection.

$108.52

vs last close0.00 (0.00%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	21	30	27	32	29	38	32	36	36	44	41	45
Cost of revenue	48	49	49	50	51	54	52	53	50	55	21	57
Gross profit	−27	−19	−22	−18	−22	−16	−20	−18	−14	−11	20	−13
	885	176	206	1,623	161	121	134	141	112	113	155	161
Research & development	80	84	102	94	78	48	54	47	49	47	48	47
	87	92	104	108	83	73	80	66	63	66	73	88
Selling & marketing	37	39	47	41	36	31	35	29	26	28	31	38
General & administrative	50	53	57	67	47	42	45	38	37	39	43	51
Other expenses	718	0	0	1,421	0	0	0	28	0	0	34	25
Operating income	−912	−195	−227	−1,641	−184	−137	−154	−159	−125	−124	−136	−174
	2	2	3	3	11	10	7	6	7	8	8	7
Interest income	3	1	3	3	12	9	8	7	6	8	8	7
Other non-operating income	−718	−2	−3	−1,421	−11	−10	−7	−28	−7	−8	−8	−7
Income before tax	−910	−193	−224	−1,638	−172	−127	−146	−153	−119	−117	−128	−167
Income tax expense	−19	−188	−6	−53	−47	−30	−40	−39	−30	−17	−34	−56
Net income from continuing operations	−891	−5	−219	−1,585	−126	−97	−106	−114	−89	−99	−93	−110
Net income	−891	−5	−219	−1,585	−126	−97	−106	−114	−89	−99	−93	−110
EPS, basic	−$28.71	−$0.18	−$7.05	−$51.06	−$3.94	−$2.89	−$3.10	−$3.18	−$2.46	−$2.44	−$2.29	−$2.56
EPS, diluted	−$28.71	−$0.18	−$7.05	−$51.06	−$3.94	−$2.89	−$3.10	−$3.18	−$2.46	−$2.44	−$2.29	−$2.56
Weighted average shares, basic	31	31	31	31	32	32	34	35	36	41	41	43
Weighted average shares, diluted	31	31	31	31	32	32	34	35	36	41	41	43
EBITDA	−154	−153	−184	−181	−133	−88	−107	−92	−80	−78	−89	−167
Depreciation & amortization	40	40	40	39	39	39	39	39	39	39	39	0
EBIT	−194	−193	−224	−220	−172	−127	−146	−131	−119	−117	−128	−167